South Africa Delays Obesity Drug Assessment

The national health department postpones the evaluation of GLP-1 medications for public obesity treatment programmes.

Updated on Oct. 28, 2026 in Weight Loss

South Africa Delays Obesity Drug Assessment

Live Poll

Should government health services provide coverage for weight-loss medications?

South Africa has delayed the assessment of GLP-1 drugs for state-funded obesity treatment programmes. Officials are currently prioritising the integration of these medicines for diabetes patients within the public healthcare sector.

Why it matters

As the nation with the highest obesity prevalence in Sub-Saharan Africa, South Africa seeks to manage costs and integrate effective care into primary healthcare services. The department anticipates that prices will continue to drop as generic competition expands.

The regulatory authority is currently reviewing over 12 applications for generic semaglutide, following the launch of Sun Pharma's Semagard at a price 18% lower than Ozempic. These developments follow WHO guidelines issued in December 2025 regarding obesity treatment.

The players

South African Health Products Regulatory Authority

This body is responsible for monitoring, evaluating, and regulating medicines and medical devices for use within South Africa.

World Health Organization

This is a specialised agency of the United Nations responsible for international public health.

Sun Pharma

This multinational pharmaceutical company produces and markets generic drugs and active pharmaceutical ingredients globally.

The details

The national essential medicines committee is tasked with evaluating these drugs to determine their role in state healthcare. While the patent on semaglutide expired earlier in 2026, the department is carefully weighing the rollout of these treatments for chronic obesity versus diabetes care.

September 2025: WHO adds GLP-1 drugs to its essential medicines list for diabetes.
December 2025: WHO releases guidelines for GLP-1 use in obesity treatment.
August 2026: Sun Pharma launches its generic semaglutide product, Semagard.

Health Landscape

This policy development mirrors the integration of global clinical standards into national health systems by following the World Health Organization essential medicines list. The move highlights how countries are adapting international guidelines for GLP-1 treatments to suit local public health and budgetary requirements.

Patients in the public sector may face continued wait times for state-subsidised access to GLP-1 obesity treatments while the review process continues. However, the entry of generic alternatives like Semagard into the private market could increase overall availability and lower costs for those paying out-of-pocket.

The takeaway

The move suggests a cautious approach to scaling expensive chronic therapies within public systems. Patients should consult with healthcare providers regarding current availability of generic options and alternative treatment pathways for obesity management.